Keywords
disease models
behavior
References
Samardžić J. Behavioural effects of the inverse agonists of ben-zodiazepine receptors. Beograd: Zadužbina Andrejević; 2015. (Serbian)
Mckinney WT. Animal models of depression: An overview. Psychiatr Dev 1984; 2(2): 77−96.
Fuchs E, Flugge G. Experimental animal models for the simula-tion of depression and anxiety. Dialogues Clin Neurosci 2006; 8(3): 323−33.
Wall P. Methodological and conceptual issues in the use of the elevated plus-maze as a psychological measurement instrument of animal anxiety-like behavior. Neurosci Biobehav Rev 2001; 25(3): 275−86.
Samardžić J, Savić K, Stefanović N, Matunović R, Baltezarević D, Obradović M, et al. Anxiolytic and antidepressant effect of zinc on rats and its impact on general behavioural parameters. Voj-nosanit Pregl 2013; 70(4): 391−5.
Abelaira HM, Réus GZ, Quevedo J. Animal models as tools to study the pathophysiology of depression. Rev Bras Psiquiatr 2013; 35(Suppl 2): S112−20.
Samardžić J, Jadžić D, Radovanović M, Jančić J, Obradović DI, Gojković-Bukarica LJ, et al. The effects of resveratrol on rat be-haviour in the forced swim test. Srp Arh Celok Lek 2013; 141(9−10): 582−5. (Serbian)
Samardžić J, Švob Štrac DO, Oprić D, Obradović DI. DMCM, a benzodiazepine site inverse agonist, improves active avoidance and motivation in the rat. Behav Brain Res 2012; 235(2): 195−9.
Samardžić J, Puškaš L, Obradović M, Lazić-Puškaš D, Obradović D. Antidepressant effects of an inverse agonist selective for α5 GABA-A receptors in the rat forced swim test. Acta Vet (Beo-grad) 2014; 64(1): 52−60.
Floresco SB, Geyer MA, Gold LH, Grace AA. Developing Predic-tive Animal Models and Establishing a Preclinical Trials Net-work for Assessing Treatment Effects on Cognition in Schi-zophrenia. Schizoph Bull 2005; 31(4): 888−94.
Floresco SB, Jentsch JD. Pharmacological enhancement of mem-ory and executive functioning in laboratory animals. Neurop-sychopharmacology 2011; 36(1): 227−50.
Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardžić J, Savić S, et al. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABAA receptors containing α5 sub-units, improves passive, but not active avoidance learning in rats. Brain Res 2008; 1208: 150−9.
Craver C, Darden L. Discovering mechanisms in neurobiology: The case of spatial memory. In: Machamer PK, Grush R, Mclaughlin P, editors. Theory and method in the neurosciences. Pittsburgh: University of Pittsburgh Press; 2001. p. 112−37.
Zhang F, Zhu ZQ, Liu DX, Zhang C, Gong QH, Zhu YH. Emul-sified isoflurane anesthesia decreases brain-derived neuro-trophic factor expression and induces cognitive dysfunction in adult rats. Exp Ther Med 2014; 8(2): 471−7.
Paul CM, Magda G, Abel S. Spatial memory: Theoretical basis and comparative review on experimental methods in rodents. Behav Brain Res 2009; 203(2): 151−64.
Vorhees CV, Williams MT. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006; 1(2): 848−58.
McNamara RK, Skelton RW. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Rev 1993; 18(1): 33−49.
Terry AV Jr. Spatial Navigation (Water Maze) Tasks. In: Bucca-fusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd ed. Boca Raton (FL): CRC Press; 2009.
Lipska B. To Model a Psychiatric Disorder in Animals Schi-zophrenia As a Reality Test. Neuropsychopharmacology 2000; 23(3): 223−39.
Schizophrenia Research Forum. Animal Models for Schizophrenia Research 2014. [cited 2015 Apr 26]. Available from: http://www.schizophreniaforum.org/res/animal/animal_tables.asp
Marcotte ER, Pearson DM, Srivastava LK. Animal models of schizophrenia: A critical review. J Psychiatry Neurosci 2001; 26(5): 395−410.
Porsolt RD, Moser PC, Castagné V. Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther 2010; 333(3): 632−8.
Porsolt RD, Castagné V, Hayes E, Virley D. Nonhuman primates: translational models for predicting antipsychotic-induced movement disorders. J Pharmacol Exp Ther 2013; 347(3): 542−6.
Jentsch JD. Enduring Cognitive Deficits and Cortical Do-pamine Dysfunction in Monkeys After Long-Term Ad-ministration of Phencyclidine. Science 1997; 277(5328): 953−5.
Möhler H, Boison D, Singer P, Feldon J, Pauly-Evers M, Yee BK. Glycine transporter 1 as a potential therapeutic target for schi-zophrenia-related symptoms: evidence from genetically mod-ified mouse models and pharmacological inhibition. Biochem Pharmacol 2011; 81(9): 1065−77.
Geyer M, Moghaddamn B. Animal models relevant to schizoph-renia disorders. In: Davis K, Charney D, Coyle J, Nemeroff C, edi-tors. Neuropsychopharmacology: The Fifth Generation of Progress. Washington, DC: American College of Neuropsy-chopharmacology; 2002. p. 689−701.
Jackson-Lewis V, Blesa J, Przedborski S. Animal models of Par-kinson's disease. Parkinsonism Relat Disord 2012; 18(1): 183−5.
Bové J, Perier C. Neurotoxin-based models of Parkinson's dis-ease. Neuroscience 2012; 211: 51−76.
Klinkenberg I, Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev 2010; 34(8): 1307−50.
Sarter M. Preclinical research into cognition enhancers. Trends Pharmacol Sci 2006; 27(11): 602−8.
Albelda N, Joel D. Current animal models of obsessive compul-sive disorder: An update. Neuroscience 2011; 211: 83−106.
Sesia T, Bizup B, Grace AA. Evaluation of animal models of ob-sessive-compulsive disorder: Correlation with phasic dopamine neuron activity. Int J Neuropsychopharmacol 2013; 16(6): 1295−307.
Collins A, Hill LE, Chandramohan Y, Whitcomb D, Droste SK, Reul JM, et al Exercise Improves Cognitive Responses to Psycho-logical Stress through Enhancement of Epigenetic Mechan-isms and Gene Expression in the Dentate Gyrus. PLoS ONE 2009; 4(1): e4330.
Rudolph U, Mohler H. Genetically modified animals in pharma-cological research: Future trends. Eur J Pharmacol 1999; 375(1−3): 327−37.
Obradović D, Savić M, Ugrešić N, Bokonjić D. GABAA receptors: Molecular substrate for development of new anxiolytics. Voj-nosanit Pregl 2003; 60(3): 345−52. (Serbian)
Barnes NM, Sharp T. A review of central 5-HT receptors and their functions. Neuropharmacology 1999; 38(8): 1083−152.